Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Eli Lilly's headquarters in Indianapolis

Regulatory

Lilly Wins Chinese Approval for Tirzepatide in Obesity on Heels of Novo’s Semaglutide

Eli Lilly’s tirzepatide, which has previously been approved in China for diabetes, can now also be used for chronic weight management in the world’s second most populated country.

July 22, 2024

2 min read

Tristan Manalac

GLP-1

Beyond Weight Loss: Novo and Lilly Look to Expand Their GLP-1 Pipelines

While type 2 diabetes and obesity are the primary conditions currently treated with blockbuster GLP-1 drugs, Novo Nordisk and Eli Lilly aim to enter additional markets.

July 22, 2024

4 min read

Grant Playter

Pictured: Buildings in downtown San Diego near the water

Career Advice

7 Biotech Companies Hiring in San Diego

Looking for a biotech job in San Diego? Check out these seven top companies hiring life sciences professionals like you.

July 18, 2024

1 min read

Angela Gabriel

Podcast

Pfizer’s Oral GLP-1 Push, Lilly Vs. Novo and PBMs Under Pressure

Pfizer selects its candidate for the oral GLP-1 race as Eli Lilly strives to overtake Novo Nordisk in the injectable weight-loss drug space. Meanwhile, pressure builds to reduce drug prices in the U.S.

July 17, 2024

1 min read

Heather McKenzie

Weight loss

Will Eli Lilly Overtake Novo Nordisk in Weight-Loss Drug Race?  

Some analysts say so, and a recent study suggested Lilly’s tirzepatide beat Novo’s semaglutide at inducing weight loss, but there are other factors in the market race. 

July 16, 2024

4 min read

Tyler Patchen

Podcast

Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists

Eli Lilly becomes the latest to make a major investment in immunology and inflammation, while antibody-drug conjugate biopharma Myricx Bio nets a large Series A round and new research highlights the potential and possible risks of GLP-1s.

July 10, 2024

1 min read

Greg Slabodkin

Hand holding an antimicrobial test over a vivid green background

Drug Development

Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma?

Investment in the development of new antimicrobials is falling rapidly, even as the global public health threat of antimicrobial resistance is growing increasingly severe worldwide.

July 10, 2024

5 min read

Ben Hargreaves

Weight Loss

Beyond GLP-1s: The Next Obesity Treatments

Eli Lilly, Rivus Pharmaceuticals and more target different biological processes in hopes of generating higher-quality weight loss and avoiding metabolic issues.

July 8, 2024

6 min read

Heather McKenzie

Podcasts

FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues

Two CRLs from the FDA last week cited concerns with third-party manufacturers, while Indian CDMOs may make a bid for U.S. business if there is a decoupling from Chinese companies under the BIOSECURE Act.

July 3, 2024

1 min read

Jef Akst

JOBS